190
Participants
Start Date
April 30, 2008
Primary Completion Date
August 31, 2009
Study Completion Date
February 28, 2010
Talactoferrin alfa
15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
Placebo
Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
University of Pittsburgh Medical Center Presbyterian Hospital, Pittsburgh
Centre Hospitalier Angouleme, Saint-Michel
The George Washington University Hospital, Washington D.C.
Wake Forest University Baptist Medical Center, Winston-Salem
Wake Forest University Health Sciences, Winston-Salem
Duke University Medical Center, Durham
Floyd Memorial Hospital and Health Services, New Albany
Henry Ford Health System, Detroit
University of Iowa Hospitals and Clinic, Iowa City
West Suburban Medical Center, Oak Park
Rush University Medical Center, Chicago
St. Louis University, St Louis
St. John's Mercy Medical Center, St Louis
University of Kansas Medical Center, Kansas City
University of Oklahoma Health Science Center, Oklahoma City
Scott & White Memorial Hospital, Temple
Ben Taub General Hospital, Houston
The Methodist Hospital, Houston
The University of Texas MD Anderson Cancer Center, Houston
Texas Tech University Health Sciences Center, El Paso
Denver Health Medical Center, Denver
Centre Hospitalier de Montauban, Montauban
Intermountain Medical Center, Salt Lake City
Olive View- UCLA Medical Center, Sylmar
Loma Linda University Medical Center, Loma Linda
UC Davis Medical Center, Sacramento
Helios Klinikum Erfurt, Erfurt
Baystate Medical Center, Springfield
Cooper University Hospital, Camden
Rhode Island Hospital, Providence
Vancouver General Hospital, Vancouver
Kingston General Hospital, Kingston
Hospital de Sabadell, Sabadell
Hospital Mutua de Terrassa, Terrassa
Lead Sponsor
Agennix
INDUSTRY